EUCTR2004-001200-12-GB进行中（未招募）不适用
INEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - N/A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects with signs or symptoms consistent with infection, and if available, laboratory findings consistent with staphylococcal infection (e.g., Gram stain and culture results). It is not a requirement to have the results of a Gram stain or culture prior to subject enrollment.
- •2. Subject or his/her legally acceptable representative must give informed consent by signing and dating an informed consent form prior to study entry.
- •3. Subjects must be at least 18 years of age.
- •4. Women of childbearing potential must use adequate contraception, defined as hormonal contraception, intrauterine device, or barrier methods (condom or vaginal diaphragm) with spermicide, throughout the study. The pre-study pregnancy test (urine or serum gonadotropin) must be negative. Women who have been surgically sterilized or are at least two years postmenopausal may be enrolled and do not have to use birth control. Women whose method of birth control is hormonal are required to use an additional barrier method during the study.
- •5. Subjects must be in a hospital environment at the time of first study dose. Non-hospitalized subjects may be enrolled as long as the first dose of study drug is given in a hospital environment. A hospital environment can include an emergency room, long term care facility such as a nursing home or rehabilitation center, or a wound center/infusion center/ambulatory treatment center that is at or attached to the hospital site.
- •6. Subjects must be expected to survive with effective antibiotic therapy and appropriate supportive care throughout the period of treatment and follow-up.
- •7. Subjects must be willing to complete all study related activities.
- •8. Subjects who, after control of their acute infection, are likely to be eligible to be discharged to outpatient therapy. In addition, the following subjects who may require long term hospitalization can be enrolled:
- •·Trauma and orthopedic patients with infections not involving bone (or if involving bone as per exclusion #8)
- •·Subjects who are expected to require surgical treatment after the study infection has resolved during the same hospitalization (i.e., skin graft for burn or ulcer)
- •·Subjects who are randomized to the vancomycin treatment group and the study site's local health practice requires that they stay in the hospital until the end of the treatment period
- •9. Subjects must have at least two of the specific signs and symptoms of an active skin or soft tissue infection caused by suspected MRSA that involves deep tissues such as subcutaneous tissue, fascia or skeletal muscle. Signs or symptoms may include:
- •·purulent drainage
- •·swelling/induration
- •·tenderness to palpation or pain
- •·local warmth
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who have received an investigational drug during the previous 30 days or five times the plasma half-life (if known), whichever is longer or who have previously participated in any other protocol using linezolid in the past 6 months. Subjects who have previously participated in this trial are also excluded.
- •2. Subjects of childbearing potential, who are unable to take adequate contraceptive precautions, have a positive pregnancy test result within 24 hours prior to study entry, are otherwise known to be pregnant, or are currently breastfeeding an infant.
- •3. Subjects with infected devices, where the device is not removed. Subjects with the following infected devices – intravascular catheters/devices, CNS shunts, or peritoneal dialysis (PD) catheters, even if the device is removed, should be excluded.
- •4. Subjects with a hypersensitivity to vancomycin, teicoplanin, oxazolidinones or any of the excipients in the IV or oral formulation of linezolid.
- •5. Subjects with MRSA known to be non-susceptible to either of the study drugs before study entry.
- •6. Subjects who were treated with a previous antibiotic (systemic or topical) with activity against a subject's MRSA isolate (other than linezolid, vancomycin or teicoplanin) with a duration of more than 24 hours unless documented to be a treatment failure (defined as 72 hours of treatment and not responding). Treatment duration is defined as the time during which doses are administered plus time from last dose administered to next scheduled dose. The combined duration of antibiotics with activity against MRSA should not exceed 24 hours if given consecutively in the preceding 72 hours prior to first dose of study drug The treatment duration applies to any of the following timeframes:
- •·Within the 72-hour pre-enrollment period
- •·Started prior to the 72-hour pre-enrollment period and extended into this period
- •·Started during the 72-hour pre-enrollment period and extended into the study drug treatment period
- •Exception: Subjects who had greater than 24 hours of an antibiotic (other than linezolid, vancomycin or teicoplanin) that can have activity against MRSA, can be enrolled if they can show the following:
- •·MRSA isolate is non-susceptible to the antibiotic, or
- •·Institution's pattern of susceptibility indicates that the MRSA isolate is likely to not be susceptible to the antibiotic
- •·The subject has been treated for > 72 hours and was a documented treatment failure
- •Certain drugs with variable MRSA activity (e.g. fluoroquinolones, clindamycin, trimethoprim-sulfamethoxazole and tetracycline) may not be excluded if local susceptibility patterns will predict resistance and resistance is subsequently documented (Refer to Section 5.4.1).
- •7. Subjects who were treated with linezolid, vancomycin or teicoplanin with a treatment duration of more than 24 hours. The treatment duration applies to any of the following timeframes:
- •·Within the 72-hour pre-enrollment period
- •·Started prior to the 72-hour pre-enrollment period and extended into this period
- •·Started during the 72-hour pre-enrollment period and extended into the study drug treatment period
- •Subjects who were treated previously with linezolid, vancomycin or teicoplanin for the infection under study are excluded if they received a treatment duration of 72 hours or more of treatment and did not respond
- •8. Subjects with known or suspected necrotizing fasciitis, gas gangrene, gangrene, septic arthritis or osteomyelitis. Subjects
研究者
相似试验
进行中（未招募）
不适用
INEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUSinezolid is an oxazolidinone antibiotic that has a broad Gram-positive antibacterial spectrum and is effective against MRSA and vancomycin-resistant Enterococcus VRE organisms. It is available in both IV and oral forms and is 100 bioavailable same IV and oral dosing .MedDRA version: 6.1Level: HLTClassification code 10040788EUCTR2004-001200-12-ITPFIZER1,200
已完成
不适用
INEZOLID (PNU 100766) ADMINISTERED BY INTRAVENOUS AND ORAL VIA FOR THE TREATMENT OF COMPASSIVE USE IN PATIENTS WITH BACTERIAL INFECTIONS WITH SIGNIFICANT RESISTANCE-A499 Bacterial infection, unspecifiedBacterial infection, unspecifiedA499PER-052-00PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
尚未招募
1 期
Clinical evaluation for primary complex points on improving the effect of obstinate insomnia and its influence on changes of brain transmittersPersistent insomniaITMCTR2000003422Third Affiliated Hospital of Henan University of Traditional Chinese Medicine
尚未招募
4 期
Implementation of the Specific Treatment Of Problems of the Spine (STOPS) approach in Nigeria for persistent low back pain: A prospective sequential comparisoMusculoskeletal DiseasesPACTR202305707317550Federal Medical Centre Nguru154
已完成
不适用
Multivariable analysis in factors of difficult intubation using AirWay ScopeAll diseases requiring non-emergency operaiton with general anesthesiaJPRN-UMIN000002161International Medical Center, Saitama Medical University500